IBCSG 50-14 OLYMPIA

A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

More Information about this Study

Further Studies: Breast cancer

SAKK 66/22

Triple-negative (hormone-independent) breast cancer, TNBC

SAKK 23/16 TAXIS

Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement

CAMBRIA-2

Researchers are looking for a better way to treat ER+/HER2- early-stage breast cancer

SAKK 23/18 - VISION I

Breast cancer: is surgery still necessary if tumor tissue can no longer be detected following chemotherapy?

SAKK 21/23 NEODOXy

Does doxycycline improve breast cancer treatment?

IBCSG 52-15 PALLAS

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

IBCSG 67-22 PREcoopERA

A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

IBCSG 48-14 POSITIVE

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE).